
Data assessing Novo Nordisk’s investigational diabetes and obesity medication were presented at The Menopause Society's 2026 Annual Meeting.
At the National Kidney Foundation conference in Chicago, researchers presented many new studies regarding the treatment of patients with kidney disease.






